RxDoctor Payments Data

Linh Vu

Family · Maricopa, AZNPI 1730654229

Payments from drug & device makers

$5,960in general payments, 2019–2025

Across 305 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$792
  • Bayer$508
  • AstraZeneca$488
  • AbbVie$485
  • Boehringer Ingelheim$445
  • GSK$430
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$5,940100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,960 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$28,553
Medicare patients
99
Services billed
367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin75$125,644
TrulicityDulaglutide42$77,655
OzempicSemaglutide30$45,085
MounjaroTirzepatide22$42,167
JanuviaSitagliptin Phosphate26$42,158
RybelsusSemaglutide14$35,835
FarxigaDapagliflozin Propanediol29$33,922
RexultiBrexpiprazole17$31,261
LinzessLinaclotide15$21,561
ProliaDenosumab11$19,441
JanumetSitagliptin Phos/Metformin Hcl11$13,616
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$12,148
Gabapentin121$3,269
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,691
Atorvastatin Calcium336$2,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$445$125,64475 claims
Lilly USA, LLCTrulicity, Mounjaro$206$119,82264 claims
Novo NordiskOzempic, Rybelsus$792$80,92144 claims
MerckJanuvia, Janumet$69$55,77537 claims
AstraZenecaFarxiga$488$33,92229 claims
AbbVieLinzess$485$21,56115 claims
AmgenProlia$193$19,44111 claims
Sanofi-aventis U.S. LLCLantus$115$2,22913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.

Other family in Maricopa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →